Skip to main content

Articles Tagged With:

  • Most Permanent Contraception Procedures Are Performed Postpartum

    Among the 600,000 permanent contraception procedures performed in the United States each year, most procedures are performed postpartum,
    including after cesarean deliveries.

  • Hormonal IUDs Work Well for Emergency Contraception and Treating Bleeding Issues

    Clinicians are increasingly aware of strong evidence for using levonorgestrel intrauterine devices for treating some gynecological issues and for emergency contraception.

  • Acute Aortic Dissection

    Acute aortic syndromes, such as dissection, ulcers, or intramural hematomas, are infrequent presentations with a high rate of mortality. While each has a described classic presentation, the absence of these findings is not reliable to adequately exclude the diagnosis and, thus, they provide a significant challenge to emergency clinicians.

  • Update on Evaluation and Management of Chest Trauma

    Early detection and prompt management of chest trauma is essential for the survival and optimal outcome for trauma patients. The authors provide the current status of diagnostic and therapeutic modalities for the management of a patient who has sustained chest trauma.

  • Iatrogenic Cerebral Amyloid Angiopathy-Related Inflammation

    In this multicenter, retrospective case series, the authors sought to describe the co-occurrence of two rare variants of cerebral amyloid angiopathy: iatrogenic cerebral amyloid angiopathy, thought to be caused by prion-like spread of amyloid beta after seeding from neurosurgical procedures decades prior to symptom onset, and cerebral amyloid angiopathy-related inflammation, characterized by robust perivascular inflammatory response in amyloid-laden vessels. This series demonstrates that inflammation can complicate iatrogenic cerebral amyloid angiopathy, supporting a spectrum model of disease and urging multicenter study.

  • Vertigo and Altered Postural Perception: Overlapping Symptoms, Distinct Mechanisms

    Two distinct vestibular disorders, persistent postural-perceptual dizziness (PPPD) and vestibular migraine (VM), both involve vertigo as a primary symptom. Nearly half of chronic migraine patients also experience vertigo, especially those with aura and allodynia. Since PPPD is seen as a functional maladaptation and VM is associated with cortical hyperexcitability, treatment for vertigo in these two conditions should be tailored to their unique pathophysiological mechanisms.

  • Progressive Encephalomyelitis with Rigidity and Myoclonus with GlyR Antibodies

    This is a retrospective observational study of patients with a clinical diagnosis of progressive encephalomyelitis with rigidity and myoclonus (PERM) and glycine receptor (GlyR) antibodies identified at a specialized neuroimmunology laboratory, as well as an accompanying systematic literature review. The goal of the study was to describe the clinical features and long-term outcome of patients with GlyR antibody-mediated PERM.

  • Relationship Between Abnormal Amyloid-β Deposition and Regional Brain Atrophy on MRI

    In a retrospective review of patients followed in the Wisconsin Alzheimer Disease Research Center, the time course of early deposition of amyloid-β correlated with regional atrophy in temporoparietal regions of interest independent of tau positivity.

  • Home Training for Cerebellar Ataxias: A Randomized Clinical Trial

    In this randomized clinical trial comparing home high-intensity aerobic training to home balance training among individuals with cerebellar ataxias, investigators found that home high-intensity aerobic training improved ataxia symptoms, fatigue, and aerobic fitness more than dose-matched home balance training.

  • Elinzanetant Capsules (Lynkuet)

    The U.S. Food and Drug Administration has approved elinzanetant, a second non-hormonal neurokinin receptor antagonist, following fezolinetant (Veozah), for the treatment of vasomotor symptoms associated with menopause. Elinzanetant is distributed by Bayer HealthCare Pharmaceuticals, Inc., as Lynkuet.